Thymalin
Thymulin, Thymic Factor, Serum Thymic Factor, Facteur Thymique Serique
Completed
PHASE3
INTERVENTIONAL
NCT00259272
Validation of Multidimensional Assessment of THYmic States (MATHYS): A Study in a Population of Bipolar Patients Treated With Olanzapine
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
A non randomized study to validate the MATHYS Scale in a population of in and outpatients greater than or equal to 18 years of age, suffering from Bipolar Disorder I or II, and treated with olanzapine.
Interventions
Name:
olanzapine
Type:
DRUG
Description:
5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
Primary Outcomes
Measure:
Mean Changes From Baseline to 6 Week and 24 Week Endpoints in the Multidimensional Assessment of THYmic States Scale (MATHYS) Total Score
TimeFrame:
Baseline, 6 Weeks, 24 weeks
Description:
A visual analogic scale consisting of 20 items. Item scores vary from 0 (inhibition of the state evaluated by the item) to 10 (excitation for the evaluated state), except for items 5 to 10 and 17 and 18 which are inversed and are consequently to be reversed before the analysis. Total score is sum of the 20 items and can vary from 0 to 200.
Measure:
Baseline MATHYS Assessment - Principal Component Analysis and Orthogonal Transformation Matrix
TimeFrame:
Baseline
Description:
This analysis indicates whether the total score is correct and provides enough information, or if subscores need to be calculated. Eigen value, proportion and cumulative are statistical parameters from the Principal Component Analysis, given for each factor.
Trial Information
NCT ID
NCT00259272
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE3
Sponsor
Eli Lilly and Company
Last Updated
December 15, 2025